AI Tool Comparison
Comparing as AI Medical Research & Clinical Decision SupportTempus AI vs Insilico Medicine
Tempus AI
VS
Insilico Medicine
Verdict by Category
Detailed category analysis is not available for this comparison.
Detailed Comparison
Feature
Tempus AI
Insilico Medicine
Pricing
CustomTempus operates multiple revenue streams with different access models.
Clinical genomic tests (xT, xG, xR, xF, xE) are ordered by physicians through the standard laboratory test ordering process. Pricing varies by test type and is typically covered by insurance for oncology patients. Tempus works directly with health systems to integrate ordering into EHR workflows.
Enterprise data platform access, Algos population health analytics, and biopharma research partnerships are priced through custom enterprise licensing agreements. Biopharma companies license Tempus's de-identified patient datasets and analytical services for drug development and clinical trial design.
Tempus is publicly traded on NASDAQ (ticker: TEM) since June 2024. Investor and enterprise partnership inquiries can be directed through tempus.com.
CustomInsilico Medicine operates through two revenue streams: platform licensing and internal drug pipeline development.
Platform access: Pharmaceutical and biotech companies license the Pharma.AI platform (PandaOmics, Chemistry42, InClinico) through enterprise agreements for target identification, molecule design, and clinical prediction. Revenue is structured as upfront platform fees, milestone payments tied to drug program progress, and royalties on commercialized drugs.
Pipeline partnerships: Insilico licenses its AI-discovered drug candidates to pharma companies (e.g., Sanofi, Exelixis) for multi-million/billion dollar deals with upfront + milestone structures. Total revenue grew from $4.5M (2021) to $85M (2024). Contact Insilico through insilico.com for licensing and partnership inquiries.
Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare ToolsAI Research & Education Tools
Summary
AI precision medicine platform — genomic profiling, clinical insights, and trial matching for personalized cancer care
Generative AI drug discovery platform — from target identification to Phase 3 clinical trials with Pharma.AI
Tempus AI Pros & Cons
Pros
- Publicly traded (NASDAQ: TEM) — one of the most credible precision medicine AI companies
- 7M+ de-identified patient records — one of the world's largest clinical-molecular datasets
- Comprehensive genomic testing across 6 test types covering all major oncology applications
- Tempus One AI provides real-time clinical insights at the point of care
- TIME Trial dramatically improves clinical trial matching and enrollment rates
- 3,800+ employees and $8.79B total capital raised since founding
- Expanding beyond oncology into neuropsychiatry, cardiology, and infectious disease
Cons
- Enterprise and institutional pricing — not accessible to individual clinicians or small practices
- Focused primarily on oncology and genomics — not a general-purpose clinical AI tool
- Genomic test turnaround requires laboratory processing time
- Data platform access and licensing requires formal agreements
- Some AI insights require institutional genomic data infrastructure to fully leverage
Insilico Medicine Pros & Cons
Pros
- World's most advanced fully AI-designed drug — rentosertib in Phase 3 for IPF (2026)
- End-to-end Pharma.AI platform covers target ID through clinical prediction in one system
- 300+ patents and 200+ peer-reviewed papers — strongest scientific publication record in AI drug discovery
- Revenue grew from $4.5M to $85M in 3 years — commercially proven licensing model
- Automated robotic lab in Suzhou closing the loop between AI design and physical testing
- Global presence: US, China, Canada, Middle East — with partnerships across big pharma
- Listed on Hong Kong Stock Exchange (HKEX: 3696) — public company with institutional backing
Cons
- Pipeline still in early-to-mid clinical stages — commercial drugs not yet approved
- Business model complexity — revenue from licensing deals is lumpy and milestone-dependent
- Dual-track model (platform + internal pipeline) adds operational complexity
- Regulatory timelines in pharma are long — AI acceleration doesn't remove all delays
- Listed on HKEX (Hong Kong) — less accessible to US institutional investors